Search results (14)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
OCION Funding Scheme: In conversation with David Church and Luciana Gneo
10 May 2024
The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardees, David Church and Luciana Gneo, to discuss what research the fund will enable them to carry out.
Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies
17 July 2023
Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
Profiling the entire cancer genome identifies new subgroups of blood cancer that can be used to predict likely clinical outcomes
4 November 2022
The University of Oxford has led the largest and most comprehensive analysis of the entire genomic landscape of the commonest type of blood cancer called chronic lymphocytic leukaemia (CLL) as part of the UK’s 100,000 Genomes Project
How Oxford has shaped cancer science
4 February 2022
As part of World Cancer Day 2022 we are diving into 10 of Oxford’s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.
Protein structure solution paves way for improved anti-cancer drugs
16 July 2021
A new study from the Newstead group at the Department of Biochemistry has solved the structure of the human folate transporter, paving the way for improved anticancer drugs.
Study investigating targeted drug delivery by focused ultrasound for pancreatic cancer opens
2 July 2021
University of Oxford researchers have begun recruitment to a study looking at whether chemotherapy medication can reach pancreatic tumours more effectively if encapsulated within a heat-sensitive shell and triggered with focused ultrasound.
T-cell landscape mapping identifies new targets for pancreatic cancer immunotherapy
13 April 2021
Through analysis of T-cell populations, Oxford pancreatic researchers identify novel therapeutic opportunities in pancreatic cancer patients
Novel imaging device enters first round of development funding programme
29 March 2021
Anna Vella is designing CAPULET: a device to increase the accuracy in delivering particle beam radiotherapy in cancer treatment
New partnership enables access to state-of-the-art radiotherapy machine
25 March 2021
University of Oxford, OUH and GenesisCare have partnered to provide access to a new ViewRay MRIdian machine. It is the first of its kind in the UK and will help to improve challenging cancer treatment through faster, tailored radiotherapy.
“The Oxford Classic” classification system uncovers new information about ovarian cancers
14 January 2021
Oxford cancer researchers have developed a new way of subtyping ovarian cancer that enables the accurate prediction of patient outcome and sheds light onto the role the immune system plays in ovarian cancer response to treatment.
Innovative drug delivery techniques show promise in clinical trials
2 November 2020
Dr Laura Spiers talks about the TarDox and PanDox trials, which are using novel drug delivery techniques to improve the uptake of chemotherapy drugs into pancreatic tumours and other cancers
Therapeutic potential for breast cancer found in the matrix
1 October 2020
Work currently underway in the laboratory of Prof Kim Midwood is investigating the therapeutic anti-cancer potential of tenascin-C, a molecule found in the extracellular matrix of breast cancer
Using DNA & RNA to treat cancers
5 August 2020
Cancer research UK Oxford Centre Development Fund Awardees Ysobel Baker and Tom Brown investigate the potential of DNA and RNA molecules as precision cancer treatments
Drug target potential for myelofibrosis
10 June 2020
A new paper published from Dr Bethan Psaila has revealed potential new immunotherapy drug targets in the treatment of myelofibrosis.